Bond.az White LogoBond.az Black Logo

Compass Point raises Nebius target to $260 on strong Q1

Compass Point raised Nebius price target to $260 on strong Q1 results. ARR and AI Cloud revenue surge. Read more on Bond.az.

David Wilson
ByDavid Wilson- Senior Editor
|
0

Compass Point raised its price target on Nebius Group (NASDAQ:NBIS) to $260 from $150 on Thursday while maintaining a Buy rating following the company’s first-quarter results.

Nebius reported group revenue increased 75% quarter-over-quarter to $399.0 million from $227.7 million. AI Cloud revenue rose 82% to $389.7 million and accounted for 98% of total Q1 revenue. The stock has rallied 474% over the past year, trading at $207.27 with a market cap of $53.1 billion.

Annual recurring revenue (ARR) increased to $1.92 billion. Adjusted EBITDA rose to $129.5 million, with AI Cloud adjusted EBITDA margin expanding to 45%. Deferred revenue hit $4.78 billion, while cash rose to $9.30 billion.

The company’s fiscal 2026 ARR target stands at $7 billion to $9 billion. Compass Point initiated coverage on February 18.

In other news, Nebius Group reported impressive Q1 2026 results, with EPS of $171.54 versus a forecast of -$62.2, and revenue of $32.44 billion, beating estimates. Analysts from Goldman Sachs, Wolfe Research, Citizens, and DA Davidson have issued positive ratings.

More News
Today / 13:32
|
872

Marvell price target raised to $200 by RBC on optical strength

RBC Capital raised Marvell Technology price target to $200, citing optical business strength. AI networking and custom XPU trends support growth.

0
Today / 13:03
|
769

Morgan Stanley Upgrades Assurant Stock Rating

Morgan Stanley upgrades Assurant stock to Overweight, raises price target to $285. Strong earnings and growth outlook highlighted.

0
Today / 12:41
|
890

Biogen Stock Rises as Stifel Maintains Buy

Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.

0
Today / 11:44
|
476

H.C. Wainwright Reiterates Immunic Stock Rating

H.C. Wainwright maintains Buy rating and $22 price target on Immunic stock. The company awaits pivotal MS drug trial results. Read more on Bond.az.

0
Today / 11:43
|
800

H.C. Wainwright Reiterates Kamada Buy Rating

H.C. Wainwright reaffirms Buy rating on Kamada with $13 target. Kamada expects double-digit revenue growth in 2026.

0
Today / 11:42
|
902

Titan Mining Price Target Cut by H.C. Wainwright

H.C. Wainwright cuts Titan Mining price target to $6.50, maintains Buy. Stock up 357% in a year, but Bond.az flags overvaluation risk.

0
Today / 11:41
|
334

Avino Silver & Gold Target Raised by Analyst

H.C. Wainwright raises Avino Silver & Gold price target to $13.00 after strong earnings report with 109% revenue growth.

0
Today / 11:05
|
279

Truist reiterates Buy on Uber stock

Truist Securities reiterates Buy on Uber stock with $112 target, citing AV strength and growth potential.

0
Today / 11:04
|
241

CrowdStrike target raised to $621 by BTIG | Bond.az

BTIG raises CrowdStrike stock price target to $621, citing platform growth and partner feedback. Stock up 20% YTD.

0
Today / 11:02
|
419

Truist raises CG Oncology target to $82 on NMIBC data

Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.

0
Today / 11:01
|
308

Morgan Stanley cuts Amcor price target to $42

Morgan Stanley cuts Amcor price target to $42 from $44, citing lower EPS and EBIT forecasts. Stock near 52-week low.

0
Today / 10:04
|
653

Morgan Stanley Cuts Global-E Online Price Target

Morgan Stanley cuts Global-E Online price target to $37, maintains Overweight rating. Stock near 52-week low with 15.6% weekly decline. Find more insights.

0
...
Compass Point raises Nebius target to $260 on strong Q1 | Bond.az